Stocks / Healthcare

Somalogic Inc

SLGC Stock Report
Current Price
XXXX
Analyst Target Price
$3.93
Market Cap
XXXX
Updated
February 27, 2025
Analysts
4

Somalogic Inc Stock Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding … More details ➜
1 Year Price Range
Low $0.00 Current High $0.00
PinkLion Scores

Fundamentals Summary

P/E Ratio
-
P/S Ratio
4.85x
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
September 30, 2023
Earnings per share (EPS) $-0.69
Gross Margin -13.79%
Net Profit Margin -159.54%
Debt/Equity Ratio -71.82%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for SLGC to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for SLGC by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
April 23, 2021
Employees
451
Sector
Healthcare
Industry
Health Information Services
Country
USA
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.